Literature DB >> 15527707

Diagnosis of the antiphospholipid syndrome: how far to go?

Joan T Merrill1.   

Abstract

The past decade has seen an evolution in the way that thrombophilic conditions are diagnosed and understood. This has largely evolved through the detection of single nucleotide polymorphisms in critical regulating proteins that are thought to confer significant structural-functional changes at key points in the coagulation cascade. The antiphospholipid syndrome (APS) is a complex hypercoagulable disorder that as yet defies the possibility of simple, predictive testing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15527707     DOI: 10.1007/s11926-004-0027-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  30 in total

1.  Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.

Authors:  Emily Somers; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

2.  Prevalence and isotype distribution of antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus (SLE).

Authors:  V Aguirre; R Cuchacovich; L Barria; H Aris; C Trejo; L Massardo; R Pasten; L Espinoza
Journal:  Lupus       Date:  2001       Impact factor: 2.911

3.  Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus.

Authors:  F J Muñoz-Rodríguez; J C Reverter; J Font; D Tàssies; G Espinosa; R Cervera; F Carmona; J Balsch; M Ingelmo; A Ordinas
Journal:  Lupus       Date:  2002       Impact factor: 2.911

4.  Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications.

Authors:  J Nojima; H Kuratsune; E Suehisa; Y Futsukaichi; H Yamanishi; T Machii; Y Iwatani; Y Kanakura
Journal:  Clin Chem       Date:  2001-06       Impact factor: 8.327

Review 5.  Which antiphospholipid antibodies should be measured in the antiphospholipid syndrome?

Authors:  M Galli
Journal:  Haemostasis       Date:  2000

Review 6.  Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations.

Authors:  T Avcin; R Cimaz; P L Meroni
Journal:  Lupus       Date:  2002       Impact factor: 2.911

7.  Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance.

Authors:  Maria Laura Bertolaccini; Giovanni Sanna; Shvaita Ralhan; Laura C Gennari; Joan T Merrill; Munther A Khamashta; Graham R V Hughes
Journal:  Thromb Haemost       Date:  2003-10       Impact factor: 5.249

8.  IgG anti-beta(2) glycoprotein I antibodies in Malaysian patients with antiphospholipid syndrome and systemic lupus erythematosus: prevalence and clinical correlations.

Authors:  S G Ong; H M Cheng; S C Soon; E Goh; S K Chow; S S Yeap
Journal:  Clin Rheumatol       Date:  2002-09       Impact factor: 2.980

9.  Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus.

Authors:  Antonio Amoroso; Anna P Mitterhofer; Flavia Del Porto; Pierluigi Garzia; Gianni M Ferri; Sara Galluzzo; Marta Vadacca; Domenico Caccavo; Antonella Afeltra
Journal:  Hum Immunol       Date:  2003-02       Impact factor: 2.850

10.  Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients with pregnancy morbidity.

Authors:  S Carmo-Pereira; M L Bertolaccini; A Escudero-Contreras; M A Khamashta; G R V Hughes
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.